Paul J. Atkins, Ph.D.

Dr. Atkins co-founded Oriel Therapeutics Inc. in 2002. Prior to starting Oriel, he spent more than ten years with GlaxoSmithKline where he held various commercial strategy, global project management and product development roles, primarily of inhalation products. During his career Dr. Atkins worked in both the United Kingdom and the USA including positions with Upjohn (Pfizer) and Fisons (sanofi-aventis) before joining Glaxo in 1991 where he established the Inhaled Product Development group and was responsible for a number of global technical development programs, including the development of HFA metered dose inhalers and novel dry powder inhalers.

Dr. Atkins earned his Ph.D. from the University of London. He is internationally recognized as an expert in the inhaled product development area and has been a member MTOC since 1996 and an advisor/consultant to both UNEP and UNDP since 2002. He is the recipient of the 2008 EPA Stratospheric Ozone Protection Award.